Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/110769
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChaccour, Carlos-
dc.contributor.authorRabinovich, Regina-
dc.date.accessioned2017-05-10T13:26:31Z-
dc.date.available2017-05-10T13:26:31Z-
dc.date.issued2017-04-24-
dc.identifier.issn1475-2875-
dc.identifier.urihttps://hdl.handle.net/2445/110769-
dc.description.abstractThe development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.-
dc.format.extent13 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBiomed Central-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/s12936-017-1802-3-
dc.relation.ispartofMalaria Journal, 2017, vol. 16, num. 1, p. 166-
dc.relation.urihttp://dx.doi.org/10.1186/s12936-017-1802-3-
dc.rightscc by (c) Chaccour et al., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationMalària-
dc.subject.classificationAssaigs clínics-
dc.subject.otherMalaria-
dc.subject.otherClinical trials-
dc.titleIvermectin to reduce malaria transmission II. Considerations regarding clinical development pathway-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2017-05-03T18:01:50Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid28434405-
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
chaccour2017_2515.pdf1.05 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons